[關(guān)鍵詞]
[摘要]
目的 探討卡格列凈聯(lián)合吡格列酮治療2型糖尿病的臨床療效。方法 選擇2020年10月—2021年10月在鞏義市人民醫(yī)院治療的84例糖尿病患者,隨機(jī)分為對照組和治療組,每組各42例。對照組口服鹽酸吡格列酮片,15~30 mg/次,1次/d。在對照組的基礎(chǔ)上,治療組口服卡格列凈片,100 g/次,1次/d。兩組連續(xù)用藥治療6周。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀緩解時間,空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血紅蛋白(HbA1c)、白細(xì)胞介素-6(IL-6)、γ干擾素(INF-γ)、腫瘤壞死因子-α(TNF-α)和C反應(yīng)蛋白(CRP)水平。結(jié)果 治療后,治療組臨床有效率為97.62%,顯著高于對照組的78.57%(P<0.05)。治療后,治療組患者多飲、消瘦、多尿、乏力等癥狀緩解時間均明顯短于對照組(P<0.05)。治療后,兩組FBG、2 h PBG、HbA1c、IL-6、INF-γ、TNF-α、CRP水平均明顯下降(P<0.05),且治療組水平明顯低于對照組(P<0.05)。結(jié)論 卡格列凈與吡格列酮聯(lián)合治療2型糖尿病,可明顯控制患者血糖水平,改善炎癥反應(yīng),有效緩解癥狀。
[Key word]
[Abstract]
Objective To investigate the efficacy of canagliflozin combined with pioglitazone in treatment of type 2 diabetes. Methods Patients (84 cases) with type 2 diabetes in Gongyi City People’s Hospital from October 2020 to October 2021 were randomly divided into control and treatment group, and each group had 42 cases. Patients in the control group were po administered with Pioglitazone Hydrochlorid Tablets, 15 — 30 mg/time, once daily. Patients in the treatment group were po administered with Canagliflozin Tablets on the basis of the control group, 100 g/time, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the levels of FBG, 2 h PBG, HbA1c, IL-6, INF-γ, TNF-α and CRP in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 97.62%, which was significantly higher than 78.57% in the control group (P < 0.05). After treatment, the remission time of symptoms such as excessive drinking, weight loss, polyuria and fatigue in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the levels of FBG, 2 h PBG, HbA1c, IL-6, INF-γ, TNF-α and CRP in two groups were significantly decreased (P < 0.05), and the levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Canagliflozin combined with pioglitazone in treatment of type 2 diabetes can obviously control the blood glucose level, improve the inflammatory reaction and effectively relieve the symptoms.
[中圖分類號]
R977
[基金項(xiàng)目]
河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目(2011020070)